19.44
2.07%
-0.41
After Hours:
19.44
Tyra Biosciences Inc stock is currently priced at $19.44, with a 24-hour trading volume of 100.91K.
It has seen a -2.07% decreased in the last 24 hours and a +4.63% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $19.67 pivot point. If it approaches the $19.19 support level, significant changes may occur.
Previous Close:
$19.85
Open:
$19.65
24h Volume:
100.91K
Market Cap:
$1.02B
Revenue:
-
Net Income/Loss:
$-69.13M
P/E Ratio:
-16.20
EPS:
-1.2
Net Cash Flow:
$-50.91M
1W Performance:
-1.72%
1M Performance:
+4.63%
6M Performance:
+31.53%
1Y Performance:
+26.32%
Tyra Biosciences Inc Stock (TYRA) Company Profile
Name
Tyra Biosciences Inc
Sector
Industry
Phone
619-728-4760
Address
2656 State Street, Carlsbad
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-30-23 | Initiated | Wedbush | Outperform |
Feb-03-23 | Initiated | Oppenheimer | Outperform |
Jun-23-22 | Initiated | H.C. Wainwright | Buy |
Mar-08-22 | Upgrade | Jefferies | Hold → Buy |
Nov-08-21 | Downgrade | Jefferies | Buy → Hold |
Oct-11-21 | Initiated | BofA Securities | Buy |
Oct-11-21 | Initiated | Cowen | Outperform |
Oct-11-21 | Initiated | Jefferies | Buy |
View All
Tyra Biosciences Inc Stock (TYRA) Latest News
Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 3.3% - MarketBeat
MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year High at $20.70 - MarketBeat
MarketBeat
Tyra Biosciences COO sells shares worth over $74000 - Investing.com India
Investing.com India
Tyra Biosciences COO sells shares worth over $74,000 By Investing.com - Investing.com Australia
Investing.com Australia
Tyra Biosciences COO sells shares worth over $74,000 By Investing.com - Investing.com UK
Investing.com UK
Kynam Capital Management LP Takes Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - MarketBeat
MarketBeat
Tyra Biosciences Inc Stock (TYRA) Financials Data
Tyra Biosciences Inc (TYRA) Net Income 2024
TYRA net income (TTM) was -$69.13 million for the quarter ending December 31, 2023, a -24.96% decrease year-over-year.
Tyra Biosciences Inc (TYRA) Cash Flow 2024
TYRA recorded a free cash flow (TTM) of -$50.91 million for the quarter ending December 31, 2023, a -0.13% decrease year-over-year.
Tyra Biosciences Inc (TYRA) Earnings per Share 2024
TYRA earnings per share (TTM) was -$1.61 for the quarter ending December 31, 2023, a -21.05% decline year-over-year.
Tyra Biosciences Inc Stock (TYRA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Bensen Daniel | Chief Operating Officer |
Jun 07 '24 |
Sale |
20.00 |
200 |
4,000 |
431,483 |
Bensen Daniel | Chief Operating Officer |
Mar 11 '24 |
Sale |
20.00 |
200 |
4,000 |
431,683 |
Bensen Daniel | Chief Operating Officer |
Mar 07 '24 |
Sale |
20.00 |
68 |
1,360 |
431,883 |
Bensen Daniel | Chief Operating Officer |
Mar 06 '24 |
Sale |
20.09 |
1,733 |
34,819 |
431,951 |
Bensen Daniel | Chief Operating Officer |
Mar 05 '24 |
Sale |
20.02 |
1,189 |
23,802 |
433,684 |
Bensen Daniel | Chief Operating Officer |
Mar 04 '24 |
Sale |
20.08 |
5,063 |
101,654 |
434,873 |
Bensen Daniel | Chief Operating Officer |
Mar 01 '24 |
Sale |
20.04 |
2,900 |
58,112 |
439,936 |
Bensen Daniel | Chief Operating Officer |
Feb 29 '24 |
Sale |
20.00 |
2,050 |
41,003 |
442,836 |
Bensen Daniel | Chief Operating Officer |
Feb 28 '24 |
Sale |
20.13 |
5,849 |
117,729 |
444,886 |
Bensen Daniel | Chief Operating Officer |
Feb 27 '24 |
Sale |
20.00 |
745 |
14,900 |
450,735 |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Cap:
|
Volume (24h):